AVIVA PLC
Estate, GB-KY6 2SD Glenrothes; Tel: +44-1592
ASSOCIATION OF INDEPENDENT RESEARCH & TECHNOLOGY ORGANISATIONS
Adr: GB-KT22 7YG Leatherhead; Tel: ++44/01372/
www.ardmel-group.co.uk; A: 1980; Eff: 175; Dev:
GBP and Euro; Cap: 40.002000 (GBP); Act: Measuring
airto@pira.co.uk; Eff: 5; Dev: £; TO: 132000; Act:
and testing equipment; Decid: R. Fernando (Director
International and national organisations. Public
General); Add: Manufacturers, Distributors.
administration; Decid: B. Blunden (President). AstraZeneca PLC ARRIVA PLC
Adr: 15 Stanhope Gate, GB- London W1K 1LN; Tel:
Adr: Admiral Way, Doxford International Business
+44/(0)20/7304 5000; Fax: +44/(0)20/7304 5151; Inet:
Park, GB- Sunderland SR3 3XP; Tel: +44/(0)191/
http://www.astrazeneca.com; A: 1999; Eff: 64.200;
5204000; Fax: +44/(0)191/5204001; Inet: http://
Dev: £, SEK, US$, Euro; Cap: 14.418.000.000 US$;
www.arriva.co.uk; A: 1997; Vat No: 176095050; Dev:
TO: 16.456.500.000 €; Act: The principal activity of
£, Euro; Cap: 471.700.000 £; TO: 1.751.100.000 £;
the group is the research, development, production
Act: Arriva is a leading European transport services
and marketing of medicines for serious health
organisation. With some 30.000 employees the Group
conditions. The group’s operation is focused on six
provides transport services - including bus, rail,
therapy areas: Cardiovascular, Gastrointestinal,
vehicle rental, water buses and demand responsive
vehicles - in Denmark, Germany, Italy, the Netherlands,
Inflammation and Infection. The group’s key products
include Atacand, Crestor, Exanta, Plendil, Seloken/Toprol-XL, Zestril, Losec/Prilosec, Nexium, Diprivan,
Board of Directors: Sir Richard Broadbent (Non-
Naropin, Seroquel, Xylocaine, Zomig, Arimidex,
Executive Chairman), Bob Davies (Chief Executive),
Casodex, Faslodex, Iressa, Nolvadex, Zoladex,
David Martin (Group Managing Director - Operations
Accolate, Oxis, Pulmicort, Rhinocort, Symbicort and
& Deputy Chief Executive), Steve Clayton (Group
Managing Director - Corporate Affairs), Steve
manufacturing sites located in 19 countries. The
Lonsdale (Group Managing Director - Finance),
group’s geographic operations are located in the
Michael Allen (Non-Executive Director), Simon Batey
United Kingdom, Belgium, France, Germany, Italy,
(Non-Executive Director), Veronica Palmer (Non-
Spain, Sweden, the Netherlands, Canada, Puerto
Rico, the United States of America, Australia andJapan; Decid: David Brennan (Board of Dir./CEO),Simon Lowth (Board of Dir./CFO), John Patterson(Board of Dir./Executive Dir.), Louis Schweitzer(Board of Dir./Non-Executive Chairman), HåkanMogren (Board of Dir./Non-Executive Vice-Chair-man); Bw: AstraZeneca UK Limited (UK),AstraZeneca Insurance Company Limited (UK),AstraZeneca Treasury Limited (UK), NV AstraZenecaSA (Belgium), AstraZeneca Dunkerque ProductionSCS (France), AstraZeneca SA (France),AstraZeneca GmbH (Germany), AstraZeneca Hol-ding GmbH (Germany), AstraZeneca SpA (Italy),AstraZeneca Farmaceutica Spain SA (Spain),AstraZeneca AB (Sweden), AstraZeneca BV (The
ARTEMIDE GB LTD
Netherlands), AstraZeneca Canada Inc. (Canada),
Adr: 106 Great Russell Street, GB-WC1B 3N London;
IPR Pharmaceuticals Inc. (Puerto Rico), AstraZeneca
Tel: +44-20 7631 5200; Fax: +44-20 7631 5222; E-
LP (USA), AstraZeneca Pharmaceuticals LP (USA),
Zeneca Holdings Inc. (USA), AstraZeneca Pty Limited
www.artemide.com; A: 1980; Eff: 15; Dev: GBP and
(Australia), AstraZeneca KK (Japan).
Euro; Cap: 650000 (GBP); TO: 5234185; Act:Electrical and electronic equipment; Decid: M. Parker
AVIVA PLC
Chief Executive Officer; Add: Manufacturers.
Adr: St Helen’s, 1 Undershaft, GB- London EC3P
Great Britain - Großbritannien - La Grande-Bretagne
Informationen und Richtlinien an Zuweiser Gerne möchten wir Ihnen mit folgendem Schreiben Informationen und Richtlinien bezüglich Interventioneller Schmerzdiagnostik und –therapie unter Bildverstärkung zukommen lassen. Insbesondere bei dringlichen Interventionen wäre es möglich, eine vorgängige Aufklärung durch den Zuweiser durchführen zu lassen, um einen möglichst schnellen Behandl
Reglement Farmaceutische zorg ONVZ Zorgverzekeraar 2010 Deel A. Algemene bepalingen Reglement Farmaceutische zorg Deel B-1. Bepalingen per geneesmiddel Onderling vervangbare geregistreerde geneesmiddelen Niet-onderling vervangbare geregistreerde geneesmiddelen Andere geneesmiddelen die op grond van de Geneesmiddelenwet in Nederland mogen worden afgeleverd Zelfzorggeneesmiddele